Gastric Cancer: Looking Beyond H. Pylori
New research into potential causes of gastric cancer is looking beyond H. pylori to other bacteria within the gastric microbiome.
Progress Against Cancer
New research into potential causes of gastric cancer is looking beyond H. pylori to other bacteria within the gastric microbiome.
Combination of radiation, chemotherapy, and immunotherapy can shrink tumors and allow surgery, with much better survival rate rather than with non-surgical treatment alone. In some cases of advanced esophageal cancer that are considered to...
Recent advances in EGFR inhibition include combinations to overcome resistance and approvals for newly diagnosed or early-stage lung cancers.
A recent study on the prevalence of cancer across different vertebrate species may provide insights into cancer mechanisms in humans.
Animals with longer gestation times may have fewer cancers, but the way traits relate to cancer risk is complex. Cancer occurs in animals as well as in humans, at widely varying rates among different...
The study, published in an AACR journal, comes after an FDA warning regarding the potential for secondary malignancies after CAR T cells are used for B-cell lymphoma or multiple myeloma. Patients who receive CAR...
Immunotherapy may make surgery an option for patients who would be considered ineligible under traditional rules. Surgery is usually the best treatment for early-stage hepatocellular carcinoma, the most common type of liver cancer, but...
Learn how liquid biopsy could be used to detect cancer and guide treatment as researchers work to develop more noninvasive screening options.
Learn about cancer vaccines, including the various types used to treat or prevent cancer, and discover what's on the horizon.
Patients given waivers to participate in A trial had outcomes the same or slightly better than people who met the standard requirements; findings support broader and more inclusive trial designs. Cancer patients sometimes find...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More